An issue of Endo International PLC (NASDAQ:ENDP) bonds fell 1.1% against their face value during trading on Monday. The high-yield issue of debt has a 5.375% coupon and is set to mature on January 15, 2023. The debt is now trading at $86.50 and was trading at $84.25 one week ago. Price changes in a company’s bonds in credit markets sometimes anticipate parallel changes in its stock price.
ENDP has been the topic of several recent research reports. William Blair reissued a “market perform” rating on shares of Endo International PLC in a research note on Wednesday, June 14th. Stifel Nicolaus downgraded Endo International PLC from a “buy” rating to a “hold” rating and dropped their price target for the company from $22.00 to $15.00 in a research note on Friday, June 9th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $9.00 price target (down previously from $15.00) on shares of Endo International PLC in a research note on Wednesday, August 9th. Vetr raised Endo International PLC from a “strong sell” rating to a “sell” rating and set a $11.34 price target on the stock in a research note on Wednesday, May 17th. Finally, Morgan Stanley lowered their target price on Endo International PLC from $12.00 to $8.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 10th. Three research analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $14.75.
Shares of Endo International PLC (NASDAQ ENDP) opened at 8.72 on Friday. The stock has a 50 day moving average of $10.47 and a 200-day moving average of $11.43. Endo International PLC has a 52-week low of $7.41 and a 52-week high of $24.93. The firm’s market capitalization is $1.95 billion.
Endo International PLC (NASDAQ:ENDP) last posted its quarterly earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.19. The business had revenue of $875.73 million during the quarter, compared to analyst estimates of $832.66 million. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The company’s revenue was down 4.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.86 earnings per share. Equities analysts expect that Endo International PLC will post $3.52 earnings per share for the current fiscal year.
In related news, CFO Blaise Coleman bought 6,500 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The stock was purchased at an average price of $7.89 per share, for a total transaction of $51,285.00. Following the completion of the transaction, the chief financial officer now owns 13,729 shares in the company, valued at $108,321.81. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Terrance J. Coughlin bought 20,000 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The shares were bought at an average price of $7.70 per share, with a total value of $154,000.00. Following the transaction, the chief operating officer now owns 181,369 shares of the company’s stock, valued at approximately $1,396,541.30. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 36,000 shares of company stock valued at $279,460. Company insiders own 0.50% of the company’s stock.
Several institutional investors have recently modified their holdings of ENDP. First Quadrant L P CA acquired a new position in Endo International PLC during the first quarter valued at approximately $24,556,000. OppenheimerFunds Inc. raised its position in Endo International PLC by 182.9% in the first quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock valued at $32,065,000 after buying an additional 1,857,678 shares during the period. Bank of New York Mellon Corp raised its position in Endo International PLC by 38.7% in the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock valued at $25,345,000 after buying an additional 633,904 shares during the period. Diamond Hill Capital Management Inc. acquired a new position in Endo International PLC during the second quarter valued at approximately $5,454,000. Finally, Ameriprise Financial Inc. raised its position in Endo International PLC by 685.0% in the first quarter. Ameriprise Financial Inc. now owns 554,138 shares of the company’s stock valued at $6,185,000 after buying an additional 483,545 shares during the period. Hedge funds and other institutional investors own 92.27% of the company’s stock.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
What are top analysts saying about Endo International PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Endo International PLC and related companies.